Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism: A Single-Center Randomized Controlled Trial in Pakistan

NCT07774273 is registered in ClinicalTrials.gov with Combined military hospital lahore as lead sponsor.

NCT NCT07774273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07774273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bleeding Risk With Apixaban Versus Rivaroxaban in Acute Pulmonary Embolism: A Single-Center Randomized Controlled Trial in Pakistan
Lead sponsor
Combined military hospital lahore
Phase
Not applicable
Overall status
Completed
Start date
January 1, 2021
Completion date
February 15, 2026
Enrollment
540 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary embolism acute, venous thromboembolism (vte)